ChiCTR2400092514 版本V1.0 版本创建时间2024/11/18 16:55:27 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2400092514 

最近更新日期:

Date of Last Refreshed on:

2024-11-18 16:54:56 

注册时间:

Date of Registration:

2024-11-18 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

火针与30%水杨酸治疗寻常痤疮的疗效与机制研究

Public title:

The Efficacy and Mechanisms of Fire Needling and 30% Salicylic Acid in the Treatment of Common Acne

注册题目简写:

English Acronym:

研究课题的正式科学名称:

火针联合30%水杨酸治疗寻常痤疮的疗效与机制研究

Scientific title:

The Efficacy and Mechanisms of Fire Needling Combined with 30% Salicylic Acid in the Treatment of Common Acne

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

王瑞娥 

研究负责人:

刘艳 

Applicant:

Ruie Wang 

Study leader:

Yan Liu 

申请注册联系人电话:

Applicant telephone:

+86 188 6181 9105

研究负责人电话:

Study leader's
telephone:

+86 189 9136 0405

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

wre19971118@163.com

研究负责人电子邮件:

Study leader's E-mail:

liuyan95@126.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

陕西省西安市新城区西五路157号西安交通大学

研究负责人通讯地址:

陕西省西安市新城区西五路157号西安交通大学

Applicant address:

Xi'an Jiaotong University, No. 157, Xiwu Road, Xincheng District, Xi'an City, Shaanxi Province

Study leader's address:

Xi'an Jiaotong University, No. 157, Xiwu Road, Xincheng District, Xi'an City, Shaanxi Province

申请注册联系人邮政编码:

Applicant postcode:

710004

研究负责人邮政编码:

Study leader's postcode:

710004

申请人所在单位:

西安交通大学

Applicant's institution:

Xi'an Jiaotong University

研究负责人所在单位:

西安交通大学第二附属医院

Affiliation of the Leader:

The Second Affiliated Hospital of Xi'an Jiaotong University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2024伦审050

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

西安交通大学第二附属医院伦理审查委员会

Name of the ethic committee:

Medical Ethical Committee of the Second Affiliated Hospital of Xi’an Jiaotong University

伦理委员会批准日期:

Date of approved by ethic committee:

2024-03-26 00:00:00

伦理委员会联系人:

肖生祥

Contact Name of the ethic committee:

Shengxiang Xiao

伦理委员会联系地址:

陕西省西安市新城区皇城西路30号

Contact Address of the ethic committee:

No.30, Huangcheng West Road, Xincheng District, xi'an City, Shaanxi Province

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 85323473

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

西安交通大学第二附属医院

Primary sponsor:

the Department of Dermatology, the Second Affiliated Hospital of Xi'an Jiaotong University

研究实施负责(组长)单位地址:

陕西省西安市新城区皇城西路30号

Primary sponsor's address:

No.30, Huangcheng West Road, Xincheng District, xi'an City, Shaanxi Province

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

陕西

市(区县):

Country:

China

Province:

Shaanxi

City:

单位(医院):

西安交通大学第二附属医院

具体地址:

陕西省西安市新城区皇城西路30号

Institution
hospital:

the Department of Dermatology, the Second Affiliated Hospital of Xi'an Jiaotong University

Address:

No.30, Huangcheng West Road, Xincheng District, xi'an City, Shaanxi Province

经费或物资来源:

陕西省中医药管理局

Source(s) of funding:

Shaanxi Provincial Administration of Chinese Medicine

研究疾病:

痤疮  

Target disease:

Acne

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

治疗新技术临床试验 

Study phase:

New Treatment Measure Clinical Study

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

探究火针、刷酸治疗痤疮的疗效及不良反应  

Objectives of Study:

The Efficacy and Adverse Reactions of Fire Needling and Acid Peeling in the Treatment of Acne

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

(1)符合西医诊断标准及Pillsbury分类法II~III级; (2)年龄14~40岁; (3)在治疗前30天内未使用与本疾病有关的口服药物,并且在7天内未使用与本疾病有关的外用药; (4)自愿参加并知情同意者

Inclusion criteria

1.Meeting the diagnostic criteria of Western medicine and classified as Grade II–III according to the Pillsbury classification. 2.Age between 14 and 40 years. 3.Have not used any oral medication related to this condition within the past 30 days and no topical medication related to this condition within the past 7 days 4.Voluntarily participating with informed consent.

排除标准:

(1)妊娠期或哺乳期妇女,近3月对生育有要求的妇女; (2)面部患有可能引起病情加重的其他皮肤疾病,如严重脂溢性皮炎、玫瑰痤疮或其他皮炎湿疹类皮肤病以及活动性单纯疱疹、白癜风病、银屑病的患者; (3)患有严重原发性疾病,例如心血管,脑血管,肝,肾和造血系统的患者,精神疾病等; (4)晕针者、畏针者、过敏体质者、瘢痕体质者; (5)不配合治疗者; (6)化学物质所致的职业性痤疮,药物所致痤疮; (7)对本研究所使用药物过敏者;

Exclusion criteria:

(1) Pregnant or breastfeeding women, or women who have fertility-related requirements in the past three months; (2) Individuals with other skin conditions on the face that may worsen the condition, such as severe seborrheic dermatitis, rosacea, other dermatitis or eczema-like skin diseases, and active herpes simplex, vitiligo, or psoriasis; (3) Individuals with serious underlying diseases, such as cardiovascular, cerebrovascular, liver, kidney, and hematological system diseases, or mental disorders; (4) Individuals who are afraid of needles, have needle phobia, are allergic, or have a tendency to form keloids; (5) Individuals who do not cooperate with the treatment; (6) Occupational acne caused by chemical substances or drug-induced acne; (7) Individuals who are allergic to the medications used in this study.

研究实施时间:

Study execute time:

From 2024-11-25 00:00:00 To 2025-01-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2024-11-25 00:00:00 To 2024-11-30 00:00:00

干预措施:

Interventions:

组别:

30%水杨酸组

样本量:

20

Group:

30% Salicylic Acid Group

Sample size:

干预措施:

将30%水杨酸涂在治疗侧,直到结霜。然后用蒸馏中和

干预措施代码:

Intervention:

Apply 30% salicylic acid to the treated side until frosting occurs. Then neutralize with distilled water.

Intervention code:

组别:

火针组

样本量:

20

Group:

Fire Needling Group

Sample size:

干预措施:

右手拇、食、中指持1ml无菌注射器针头,置针于火焰的外焰,先加热针体,再加热针尖,把针烧至发白。选好进针点,右手运用手腕力量,持针迅速垂直刺入皮损顶部,针刺深度以针尖透过皮肤病变组织,未接触正常组织为宜。

干预措施代码:

Intervention:

Hold a 1ml sterile syringe needle with the thumb, index, and middle fingers of the right hand. Place the needle in the outer flame of the fire, first heating the needle body and then the needle tip until the tip turns white. Select the appropriate insertion point, then, using wrist movement, quickly and vertically insert the needle into the top of the lesion. The depth of the needle should be such that the tip passes through the diseased tissue without contacting the normal tissue.

Intervention code:

组别:

火针+水杨酸组

样本量:

20

Group:

Fire Needling+30% Salicylic Acid Group

Sample size:

干预措施:

先行火针治疗,再刷酸

干预措施代码:

Intervention:

ire needling treatment is performed first, followed by acid peeling.

Intervention code:

组别:

对照组

样本量:

20

Group:

Control Group

Sample size:

干预措施:

痤疮基本治疗,外用夫西地酸、阿达帕林

干预措施代码:

Intervention:

Basic acne treatment, including topical fusidic acid and adapalene.

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

陕西 

市(区县):

 

Country:

China

Province:

Shaanxi

City:

单位(医院):

西安交通大学大学第二附属医院 

单位级别:

三甲 

Institution
hospital:

the Second Affiliated Hospital of Xi'an Jiaotong University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

全球痤疮严重程度

指标类型:

主要指标

Outcome:

Global acne severity

Type:

Primary indicator

测量时间点:

测量方法:

痤疮综合分级系统(GAGS)

Measure time point of outcome:

Measure method:

gobal acne grading system,GAGS

指标中文名:

计数法

指标类型:

主要指标

Outcome:

Counting Method

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

炎症因子水平

指标类型:

次要指标

Outcome:

Inflammatory Cytokine Levels

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

不良反应

指标类型:

次要指标

Outcome:

side effects

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 14 years
最大 Max age 40 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

准备患者名单: 列出所有待分配的患者名单,给每个患者分配一个编号。使用在线随机数生成器, 将患者根据随机数排序后,按预定的分组方式分配患者。记录每个患者的编号和其分配的组别,并确保每个患者仅被分配到一个组。

Randomization Procedure (please state who generates the random number sequence and by what method):

Prepare the patient list: List all patients to be assigned and assign a number to each patient. Use an online random number generator to sort the patients based on the random numbers, then assign patients to groups according to the predetermined grouping method. Record each patient's number and their assigned group, ensuring that each patient is assigned to only one group.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

单盲,仅数据分析者不了解分组情况

Blinding:

Single blindness, where only the data analyst does not know the grouping

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

None

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表 电子采集和管理系统

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

A standard data collection and management system include a CRF and an electronic data

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2024-11-18 16:54:56